DEEP TECH DECISION DE-RISKING
& COMMERCIALiSATION STRATEGY
Know what to prove for a viable commercial pathway.
Commercial success depends on more than a working technology or the next funding round. With progress, ventures must connect who will buy, how value is created and which route to market is credible.
I independently stress-test assumptions and dependencies behind the next move.
You receive evidence-based recommendation – so founders, board, investors, partners and team can act on the same basis.
One decision in 2–3 weeks.
Scale Lab-to-Market:
What Is Too Expensive To Ignore
Customers are interested and pilots are running
– but pilots are not becoming repeatable revenue.
I INVESTIGATE How customer urgency, procurement, integration, pricing, regulation, delivery capacity and financing affect the route from interest to adoption.
YOU CAN DECIDE What is preventing conversion, which evidence customers still need and whether the commercial model can scale.
Every expert is convincing within their own domain
– technology, IP, regulation, sales, partnerships or finance –
but their recommendations do not add up to one executable strategy.
I INVESTIGATE The conflicts and dependencies between those recommendations, tested against the venture’s actual route to adoption and value.
YOU CAN DECIDE One decision logic: what matters now, what can wait and which action unlocks the next commercially relevant proof.
Another grant, programme, pilot, partnership or fundraising round could buy crucial resources
– but it is unclear where to invest now for it to eventually pay off.
I INVESTIGATE How each option affects commercial proof, capital requirements, control, timing and future constraints – not merely the next milestone.
YOU CAN DECIDE The next move most likely to change the trajectory, plus the evidence needed before committing scarce time and capital.
Several routes to market look plausible, but technology, customer adoption, IP, regulation, team and capital
cannot all advance at once. Which path should receive scarce resources first?
I INVESTIGATE How technical maturity, market demand, IP position, regulatory pathways, adoption requirements, team capacity and funding interact across viable market routes – and which dependency must be resolved first.
YOU CAN DECIDE Which market and route to pursue first, what to prove in what order, and where to commit, defer or stop scarce people and capital.
Commercialisation strategy
for science-based ventures
Capital Acquisition Strategy
For ventures that need to finance a research, validation, spinout or commercial transition without defaulting to the wrong capital.
You receive:
→ a map of suitable capital sources and their sequencing
→ venture-capital fit and viable funding opportunities
→ evidence and readiness gates for each financing step
→ alignment of technical, commercial and financing milestones
→ a written capital-acquisition strategy with leading narratives
Process: Document review, founder working session, capital pathway analysis and final readout.
Timeline: 2–3 weeks.
1
Venture Transition Review
For ventures or their funders that cannot safely make the next move on current assumptions.
You receive:
→ an independent assessment of the venture state and decision
→ the binding constraint and relevant evidence gaps
→ a comparison of credible product, market, partnership and capital routes
→ explicit conditions for the next commitment
→ a 3–5 page executive Venture Decision Brief
Process: Evidence review, up to three stakeholder conversations and decision readout.
Timeline: 4–6 weeks.
2
Venture Transition Architecture
For ventures that need to model product development, target market, buyer logic, pricing, adoption, partnerships and financing as one system.
You receive:
→ a commercial model covering first offer, beachhead, buying roles, adoption path and pricing
→ a 12–24 month integrated roadmap
technical, commercial and financing milestones
→ critical dependencies and evidence gates, route-to-market and partnership decision points
→ explicit conditions for investment, continuation or change
Process: Evidence review, targeted stakeholder interviews, architecture development and leadership workshop. Timeline: 8–12 weeks.
3
Scaling Science Ventures
& Value Creation
Commercial breadth and customer qualification
The initial problem: Which revenue opportunities should lead the financing story? Founders treated equipment sales, processing and development services as diversification around one platform. The underlying problem identified: The commercial plan was committing cash before establishing a deliverable, qualified offer that could generate receipts in time. Critical interaction: Custom development consumes the engineers needed for customer qualification, while expansion spending shortens the runway available to complete it. Decision conditions: Confirm buyer acceptance requirements, engineering availability, delivery capability and funding through qualification. Recommendation: Stage expansion around a bounded core offer; release broader commitments only when its qualification and financing path is credible. QUATISE value: Make an unaffordable commercial sequence visible before capital is committed, and focus resources on reaching the first qualified sale.